<DOC>
	<DOC>NCT00454350</DOC>
	<brief_summary>This study will measure serum levels of the active Vitamin D compound that circulates in hemodialysis subjects treated with either doxercalciferol injection (Hectorol®) or Zemplar® (paricalcitol injection).</brief_summary>
	<brief_title>A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism, Secondary</mesh_term>
	<mesh_term>1 alpha-hydroxyergocalciferol</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>The subject must be receiving hemodialysis three times per week for a minimum of three months. The subject must be receiving intravenous doxercalciferol or paricalcitol at each dialysis session (three times weekly) for a minimum of 12 weeks prior to Screening. At Screening Visit the subject's laboratory measurements must be within the following ranges: Serum iPTH measurement between 150800 pg/mL; Corrected calcium measurement ≤ 10.5 mg/dL; Serum phosphorus measurement ≤ 7 mg/dL Any ongoing use of over the counter or prescription vitamin D preparations except doxercalciferol or paricalcitol injection or multivitamins. History of heparininduced thrombocytopenia.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Hectorol (doxercalciferol injection)</keyword>
	<keyword>Zemplar (paricalcitol injection)</keyword>
</DOC>